


| Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis |
|
BREEZE-AD7, conducted outside of the United States, is the third of five placebo-controlled trials in the Phase 3 program and recruited patients from Asia Europe South America and Australia. Safety data were consistent with the known safety profile of baricitinib.
Posted: 2019-08-23 21:37:00
|
If you are a broadcaster or Christian program producer you can schedule a 15 min FREE consultation with an EGR specialist to help you evaluate all possible Int'l broadcasting options.
We will call you back at a number and time of your convenience, and will gladly answer any question that you may have on how to broadcast your Christian message worldwide.